Congestive Heart Failure and Anthracycline: A new Biomarker?

Share this content:
The A allele of the SNP rs28714259 was associated with an increased risk for developing anthracycline-induced congestive heart failure.
The A allele of the SNP rs28714259 was associated with an increased risk for developing anthracycline-induced congestive heart failure.

The A allele of the single nucleotide polymorphism (SNP) rs28714259 was associated with an increased risk for developing anthracycline-induced congestive heart failure (CHF) in women with breast cancer, according to a release.1

To evaluate associations between SNPs and cardiotoxicity associated with doxorubicin, investigators analyzed genome-wide association data from 3431 women with breast cancer who received doxorubicin while enrolled in the phase 3 Eastern Cooperative Oncology Group (ECOG) 5103 clinical trial. Among these, 2% had CHF.

Researchers identified several SNPs associated with anthracycline-related CHF and selected 2 of the top SNPs for validation in independent data sets.

rs28714259 was associated with a higher risk for developing anthracycline-induced CHF among 2415 women with breast cancer enrolled in the trial. It was also associated with low ventricular ejection fraction, a sign of cardiotoxicity, among 828 women with breast cancer in the phase 3 BEATRICE study.

RELATED: Breast Cancer: Taselisib Shows Preclinical Advantage Over Other PI3K Inhibitors

This study has 2 key limitations: because not all of the clinical trials used the same criteria for evaluating cardiotoxicity, and the number of patients with anthracycline-induced cardiotoxicity was relatively low, additional studies in other patient groups and in the “real-world” clinical setting are necessary to validate these findings.

Reference

  1. New genetic biomarker identifies patients with increased risk for heart damage caused by anthracycline chemotherapy [news release]. Philadelphia, PA: American Association for Cancer Research; December 19, 2016. Accessed December 19, 2016.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs